Trial reportPloS one2014
The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02253251 (Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Interaction between microRNA and KRAS in Glioblastoma.Current medicinal chemistry · 2026Review
- Diagnostic and prognostic potential of microRNA profiles in endometrioid endometrial cancer.Scientific reports · 2025Article
- High-intermediate risk endometrial cancer: moving toward a molecularly based risk assessment profile.International journal of clinical oncology · 2022Review
- The Role of miRNAs in the Regulation of Endometrial Cancer Invasiveness and Metastasis-A Systematic Review.Cancers · 2021Review
- Progression inference for somatic mutations in cancer.Heliyon · 2017Article
- FOXP1 forkhead transcription factor is associated with the pathogenesis of endometrial cancer.Heliyon · 2016Article
- Childhood cancer: an emerging public health issue in China.Annals of translational medicine · 2015Article
- Review
- Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2015Article
- MicroRNAS in endometrial cancer: recent advances and potential clinical applications.EXCLI journal · 2015Review
- Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Cell cycle (Georgetown, Tex.) · 2015Article
- MicroRNA-mediated regulation of KRAS in cancer.Journal of hematology & oncology · 2014Review
- The Role of Serum MicroRNA-6767-5p as a Biomarker for the Diagnosis of Polycystic Ovary Syndrome.PloS oneArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 2 countries.
Funding
Abstract
objectiveTo explore the association of a functional germline variant in the 3'-UTR of KRAS with endometrial cancer risk, as well as the association of microRNA (miRNA) signatures and the KRAS-variant with clinical characteristics and survival outcomes in two prospective RTOG endometrial cancer trials. METHODS/MATERIALS: The association of the KRAS-variant with endometrial cancer risk was evaluated by case-control analysis of 467 women with type 1 or 2 endometrial cancer and 582 age-matched controls. miRNA and DNA were isolated for expression profiling and genotyping from tumor specimens of 46 women with type 1 endometrial cancer enrolled in RTOG trials 9708 and 9905. miRNA expression levels and KRAS-variant genotype were correlated with patient and tumor characteristics, and survival outcomes were evaluated by variant allele type.
resultsThe KRAS-variant was not significantly associated with overall endometrial cancer risk (14% controls and 17% type 1 cancers), although was enriched in type 2 endometrial cancers (24%, p = 0.2). In the combined analysis of RTOG 9708/9905, miRNA expression differed by age, presence of lymphovascular invasion and KRAS-variant status. Overall survival rates at 3 years for patients with the variant and wild-type alleles were 100% and 77% (HR 0.3, p = 0.24), respectively, favoring the variant.
conclusionsThe KRAS-variant may be a genetic marker of risk for type 2 endometrial cancers. In addition, tumor miRNA expression appears to be associated with patient age, lymphovascular invasion and the KRAS-variant, supporting the hypothesis that altered tumor biology can be measured by miRNA expression, and that the KRAS-variant likely impacts endometrial tumor biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.